Takeda Faces Serial FDA Delays, Yen Appreciation And Acquisition Drags In 2008
This article was originally published in The Pink Sheet Daily
Executive Summary
Japanese firm incurs “income contraction” for the first time in 17 years.
You may also be interested in...
FDA Puts Off Forest’s Fibromyalgia Drug Milnacipran
For unknown reasons, SSNRI spending weeks in regulatory limbo.
Cancer Immunotherapy Sees Setback With Failure Of Cell Genesys’ GVAX
Cell Genesys will cut 75 percent of its workforce and explore strategic alternatives after halting development of the prostate cancer vaccine.
Takeda’s Alogliptin Falls Prey To FDA Slowdown
Delay is no bellwether for oral anti-diabetic drugs, the firm says.